Catheters in Dialysis Linked to High Risk of Infection
By HospiMedica International staff writers Posted on 03 Mar 2013 |
A new study shows that dialysis patients using catheters for blood access have the highest risks for death, infections, and cardiovascular (CV) events.
Researchers at the University of Calgary (Canada), the University of Otago (Christchurch, New Zealand), and other institutions conducted a systematic review of cohort studies to evaluate the associations between type of vascular access (arteriovenous fistula, arteriovenous graft, and central venous catheter) and risk for death, infection, and major CV events. The researchers searched MEDLINE, EMBASE, and other article reference lists and extracted data describing study design, participants, vascular access type, clinical outcomes, and risk for bias. In all, 62 cohort studies comprising 586,337 participants met the inclusion criteria.
The results showed that when compared with patients with an arteriovenous fistula, those using catheters had a 38% higher risk of experiencing a major heart-related event, a 53% higher risk of dying, and more than twice the risk of developing fatal infections. Patients with arteriovenous grafts had an 18% increased risk of dying and a 36% increased risk of developing fatal infections compared to those with an arteriovenous fistula, but they did not have an increased risk of experiencing a major heart-related event. The study was published early online on February 21, 2013, in the Journal of the American Society of Nephrology (JASN).
“Our findings are reflected in current clinical practice guidelines, which promote fistulas as the preferred form of bloodstream access in hemodialysis patients,” said lead author Pietro Ravani, MD, of the University of Calgary, and colleagues. “Better quality data are needed, but not from studies with the same design as those already available. In fact, our cumulative meta-analysis shows that this information was already available 10 years ago.”
An arteriovenous fistula is currently the most recommended access for kidney disease patients who must undergo dialysis, created by connecting a patient's vein and artery to form a long-lasting site through which blood can be removed and returned. Alternatively, in patients who are unsuitable for a fistula, an arteriovenous graft—a plastic conduit between an artery and a vein—may be used. Many patients, however, prefer a catheter, for reasons that include inadequate preparation for dialysis, avoidance of surgery, or fear of needles (since the connection to the dialysis machine via a catheter does not require needles).
Related Links:
University of Calgary
University of Otago
Researchers at the University of Calgary (Canada), the University of Otago (Christchurch, New Zealand), and other institutions conducted a systematic review of cohort studies to evaluate the associations between type of vascular access (arteriovenous fistula, arteriovenous graft, and central venous catheter) and risk for death, infection, and major CV events. The researchers searched MEDLINE, EMBASE, and other article reference lists and extracted data describing study design, participants, vascular access type, clinical outcomes, and risk for bias. In all, 62 cohort studies comprising 586,337 participants met the inclusion criteria.
The results showed that when compared with patients with an arteriovenous fistula, those using catheters had a 38% higher risk of experiencing a major heart-related event, a 53% higher risk of dying, and more than twice the risk of developing fatal infections. Patients with arteriovenous grafts had an 18% increased risk of dying and a 36% increased risk of developing fatal infections compared to those with an arteriovenous fistula, but they did not have an increased risk of experiencing a major heart-related event. The study was published early online on February 21, 2013, in the Journal of the American Society of Nephrology (JASN).
“Our findings are reflected in current clinical practice guidelines, which promote fistulas as the preferred form of bloodstream access in hemodialysis patients,” said lead author Pietro Ravani, MD, of the University of Calgary, and colleagues. “Better quality data are needed, but not from studies with the same design as those already available. In fact, our cumulative meta-analysis shows that this information was already available 10 years ago.”
An arteriovenous fistula is currently the most recommended access for kidney disease patients who must undergo dialysis, created by connecting a patient's vein and artery to form a long-lasting site through which blood can be removed and returned. Alternatively, in patients who are unsuitable for a fistula, an arteriovenous graft—a plastic conduit between an artery and a vein—may be used. Many patients, however, prefer a catheter, for reasons that include inadequate preparation for dialysis, avoidance of surgery, or fear of needles (since the connection to the dialysis machine via a catheter does not require needles).
Related Links:
University of Calgary
University of Otago
Latest Critical Care News
- Cutting-Edge Bioelectronic Device Offers Drug-Free Approach to Managing Bacterial Infections
- Early TAVR Benefits Patients with Asymptomatic Severe Aortic Stenosis
- Sophisticated Machine-Learning Approach Uses Patient EHRs to Predict Pneumonia Outcomes
- First-Of-Its-Kind Experimental Therapy Enhances Tissue Repair After Heart Attack
- AI Model Predicts Patients at Most Risk of Complication During Treatment for Advanced Kidney Failure
- AI Model Predicts Patients’ Risk of Developing and Worsening Disease from ECGs
- Grain-Sized Soft Robots Controlled by Magnetic Fields Deliver Medical Drugs
- AI Tool Helps Identify Heart Failure Risk in Diabetes Patients
- Inflammation Reducing Antibody Could Serve as Cardio-Immunotherapy for Heart Failure Patients
- AI Tool Accurately Identifies Patients Who Could Require Emergency Hospital Admission
- Simple Risk Score Model Helps Wean Patients from Mechanical Circulatory Support
- AI-Powered Wearable Camera System Detects Errors in Medication Delivery
- Re-Engineered Immune Cells Penetrate and Kill Solid Tumors
- New Nanoparticle Nanotherapy Infusion Cleans Arteries
- Fluorescence Imaging a Game-Changer for Bedside Biofilm Detection
- Spongelike Bandage with Antimicrobial Efficacy Stops Hemorrhaging and Mitigates Risk of Infection